In this short 2014 clip from Horizon’s “Should we Eat Meat?” Professor Jeremy Sanderson talks to Dr Michael Mosley about the procedure.
Author Archives: admin1
British Society of Gastroenterology updates guidance on Crohn’s
We are pleased to share the recently published updated guidance on Crohn’s and Ulcerative Colitis for adults over sixteen from the British Society of Gastroenterology. It includes the first ever mention of RHB-104, the combined antibiotic pill which has been successfully trialled by Redhill Biopharma; this large RCT addresses the mycobacteria which we believe is at the root of the Crohn’s disease and which the Crohn’s MAP Vaccine is also designed to target. We are delighted to see antibiotic treatment included in the new guidance and hope that the BSG will be following the progress of the vaccine trials with interest!
Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
This is the recently published paper on safety and immunogenicity of the primer shot of the Crohn’s MAP Vaccine.
Presence of MAP Monitored Over Varying Temporal and Spatial Scales in River Catchments: Persistent Routes for Human Exposure
This recent study from Pickup et al provides evidence for the environmental continuum of Map from the grazing infected animal via rain driven runoff through field drains and streams into main rivers; with detection at a high frequency throughout the year.
Anti-HERV-WEnv antibodies are correlated with seroreactivity against MAP in children and youths at T1D risk
Several studies have associated exposure to Mycobacterium avium subsp. paratuberculosis (MAP) with increased anti-MAP seroreactivity in Type 1 Diabetes patients. The results of this new study from Sechi et al support the hypothesis of MAP infection leading to HERV-W antigen expression and enhancing the production of autoantibodies in T1D.
The Crohn’s MAP Vaccine team grows!
Amy had a meeting at the lab on Wednesday and welcomed two new members to the team!
Dr Paul Cross is a GCP (Good Clinical Practice) consultant who is working with us both in the set up of the Vaccine phase II trial at GSTT and the work on the MAP test in the lab at KCL. His role is to help us develop systems to ensure that our research is conducted to the highest standards. The complexity of rules and regulations can be quite scary so to have someone on the team with his wisdom and expertise in this area is an absolute godsend!
Dr Gaurav Agrawal is a Consultant Gastroenterologist who is joining our team as a Clinical Research Fellow and will be working alongside Prof Jeremy Sanderson to lead the Phase II Vaccine clinical trial at GSTT. He’s come all the way from Centre for Digestive Diseases (CDD), Sydney, where he’s been Prof Borody’s right-hand man for the last few years, leading the way in MAP research as well as looking after many Crohn’s patients, taking a MAP-targeted approach to treatment. Initially his involvement will be for at least six months, then he will be splitting his time between GSTT (until the trial is complete) and CDD. He is a wonderful doctor and passionate about this area of research.
The team, from left to right:
Barry Hudspith, Senior research technician
Neil Rayment, Senior research scientist
Dr Paul Cross, GCP consultant
Prof John Hermon-Taylor, project leader
Dr Gaurav Agrawal, Consultant Gastroenterologist and Clinical Research Fellow
Dr Amy Hermon-Taylor
Special edition newsletter for World MAP Day
A special, extra edition of our newsletter is out now. You can read it here.
Genetic polymorphisms in tumour necrosis factor receptors (TNFRSF1A/1B) illustrate differential treatment response to TNFα inhibitors in patients with Crohn’sdisease
This paper from Naser et al supports genotype testing before treatment with anti-TNF drugs.
“Although inhibition of TNFα has shown a positive clinical outcome in some patients with CD, poor response was also found in others, which leaves those patients with severe side effects and higher susceptibility to infections. Therefore several pharmacogenetic studies have evaluated the variation of anti-TNFα treatment response among patients with CD in order to predict treatment response ultimately.”
The SNPs TNFRSF1A:rs767455 and TNFRSF1B:rs3397, which are known to affect anti-TNFα clinical outcome in CD, were associated with lower corresponding gene expression and higher MAP infection susceptibility.
